Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose
2011
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
2015
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
2011 Standout
De novo design of modular and tunable protein biosensors
2021 StandoutNatureNobel
The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation
2016
Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma‐related mortality in elderly follicular lymphoma in the United States
2015
Gender medicine and oncology: report and consensus of an ESMO workshop
2019
A view on drug resistance in cancer
2019 StandoutNature
Management of RA medications in pregnant patients
2009
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
2006 Standout
Estrogens as neuroprotectants: Estrogenic actions in the context of cognitive aging and brain injury
2016
Rheumatoid arthritis
2016 Standout
Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP)
2003
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Gender and the Injured Brain
2008
Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology
2020 Standout
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
2009 Standout
T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura
2003
A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy
2016
Macrophagic and microglial responses after focal traumatic brain injury in the female rat
2014
Building better monoclonal antibody-based therapeutics
2015
Antibodies against platelet glycoproteins and antiphospholipid antibodies in autoimmune thrombocytopenia
1998
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura
2000
Unilateral ischemic sensorimotor cortical damage in female rats: forelimb behavioral effects and dendritic structural plasticity in the contralateral homotopic cortex
2004
Antibodies in oncology
2011
Lung cancer: current therapies and new targeted treatments
2016 Standout
Antibody therapy of cancer
2012 Standout
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
2015
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Apoptosis in cancer: from pathogenesis to treatment
2011 Standout
Inhibiting eukaryotic transcription. Which compound to choose? How to evaluate its activity?
2011 Standout
Chronic Idiopathic Thrombocytopenic Purpura
1994
Targeting apoptosis in cancer therapy
2020 Standout
Immune Thrombocytopenic Purpura
2002 Standout
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Platelets and the immune continuum
2011 Standout
High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults
2004
The Glymphatic System: A Beginner’s Guide
2015 Standout
Characterization of autoantibodies against the platelet glycoprotein antigens llb/llla in childhood idiopathic thrombocytopenia purpura
1995
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Chemotherapy as treatment of primary and recurrent small cell lung cancer
2001
Glycotherapy: New Advances Inspire a Reemergence of Glycans in Medicine
2013 StandoutNobel
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
International study to compare antigen‐specific methods used for the measurement of antiplatelet autoantibodies
1997
Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
2015
Rheumatoid arthritis
2010 Standout
BCL-2 family isoforms in apoptosis and cancer
2019 Standout
Double-Cycle, High-Dose Ifosfamide, Carboplatin, and Etoposide Followed by Peripheral Blood Stem-Cell Transplantation for Small Cell Lung Cancer
2005
Cisplatin: The first metal based anticancer drug
2019 Standout
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
2015
Impact of environmental estrogens on Yfish considering the diversity of estrogen signaling
2013
Advances in the diagnosis of idiopathic thrombocytopenic purpura
2000
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Mitochondria as multifaceted regulators of cell death
2019 Standout
Small-cell lung cancer
2005
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Platelet autoantibodies in patients with chronic liver disease
1995
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Biologic therapy and pregnancy outcomes in women with rheumatic diseases
2009
Long-Term observation of 208 adults with chronic idiopathic thrombocytopenic purpura
1995
Opportunities for Treg cell therapy for the treatment of human disease
2023 StandoutNobel
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017
IgG Subclasses and Allotypes: From Structure to Effector Functions
2014 Standout
Small-cell lung cancer
2011
A prospective study of protein‐specific assays used to investigate idiopathic thrombocytopenic purpura
1999
Chronic Histopathological and Behavioral Outcomes of Experimental Traumatic Brain Injury in Adult Male Animals
2014
Neuroinflammation: the devil is in the details
2016 Standout
Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia
2017
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
2018
EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals
2015 Standout
Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma
2016
Principles of Experience-Dependent Neural Plasticity: Implications for Rehabilitation After Brain Damage
2008 Standout
Stimulatory and Inhibitory Analogs of Luteinizing Hormone Releasing Hormone (LHRH)
1977 StandoutNobel
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology [see comments]
1996 Standout
Monoclonal Antibodies for Cancer Therapy
2012 StandoutNobel
Revised Response Criteria for Malignant Lymphoma
2007 Standout
Thoracic positron emission tomography using18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease
2001
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
2008 Standout
Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns
2012
Recombinant human natural autoantibodies against GPIIb/IIIa inhibit binding of autoantibodies from patients with AITP
1998
Novel agents for the treatment of chronic lymphocytic leukemia.
2010
Rituximab Administration in Third Trimester of Pregnancy Suppresses Neonatal B-Cell Development
2008
F‐domain valency determines outcome of signaling through the angiopoietin pathway
2021 StandoutNobel
Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma
2012
Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3
2011
Adverse Health Consequences of Performance-Enhancing Drugs: An Endocrine Society Scientific Statement
2013 Standout
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
2014
Prospective evaluation of the clinical usefulness of an antigen- specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias
1996
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
Shaping of T Cell Functions by Trogocytosis
2021
Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
2009
Flavonoids as Potential Anti-Inflammatory Molecules: A Review
2022 Standout
Ferroptosis as a target for protection against cardiomyopathy
2019 Standout
Pharmaceuticals of Emerging Concern in Aquatic Systems: Chemistry, Occurrence, Effects, and Removal Methods
2019 Standout
Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura
1994
Ibrutinib: A First in Class Covalent Inhibitor of Bruton's Tyrosine Kinase
2014
Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura
1994
The Essential Medicinal Chemistry of Curcumin
2017 Standout
Complex mixtures, complex responses: Assessing pharmaceutical mixtures using field and laboratory approaches
2015
Dual-Color Bioluminescent Sensor Proteins for Therapeutic Drug Monitoring of Antitumor Antibodies
2018
Parellel inhibition of LH-RH-induced cyclic AMP accumulation and LH and FSH release by LH-RH antagonists in vitro.
1975 StandoutNobel
Early Brain Injury Alters the Blood–Brain Barrier Phenotype in Parallel with β-Amyloid and Cognitive Changes in Adulthood
2012
Works of Michael Wenger being referenced
Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study
2013
Immunotoxic effects of environmental toxicants in fish — how to assess them?
2012
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
2017
Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma
2015
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
2017
Endocrine disrupting compounds: Can they target the immune system of fish?
2011
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer
1997
Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia
2012
17Beta-estradiol affects the response of complement components and survival of rainbow trout (Oncorhynchus mykiss) challenged by bacterial infection
2011
Evaluation of estrous cycle stage and gender on behavioral outcome after experimental traumatic brain injury
2003
Fish immunotoxicology: research at the crossroads of immunology, ecology and toxicology
2015
Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment
1993
Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
2012
The effects of rituximab treatment during pregnancy on a neonate.
2006
Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – First Results From a Phase II Study In Patients with Relapsed/Refractory DLBCL and MCL
2010
Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial
2008
Serum Levels and Pharmacokinetic of Rituximab in Bi-Weekly R-CHOP in Elderly Patients with DLBCL Treated in the RICOVER-60 Trial.
2006
Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – Updated Results with Encouraging Progression Free Survival (PFS) Data From a Phase II Study In Patients with Relapsed/Refractory Indolent NHL (iNHL)
2010
Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study
2014
Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial
2008
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL
2012
Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
2010
Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment
1993